Robert Langreth's profile photo

Robert Langreth

New York

Science and Health Reporter-at-Large at Bloomberg News

Science and health reporter at large, Bloomberg News

Featured in: Favicon bloomberg.com Favicon uol.com.br (+1) Favicon forbes.com Favicon msn.com Favicon elpais.com Favicon indiatimes.com (+1) Favicon huffpost.com Favicon independent.co.uk Favicon washingtonpost.com Favicon time.com

Articles

  • 3 days ago | bloomberg.com | Robert Langreth |Damian Garde

    Hi, it’s Bob from Chicago, where I spent my weekend talking to oncologists. And it’s Damian in New York, where I monitored the cancer conference from afar. Here’s what we learned. But first ... Every year around this time, some 40,000 oncologists and oncology drug developers from around the world descend on the massive convention center here in Chicago for the American Society of Clinical Oncology annual meeting.

  • 4 days ago | bloomberg.com | Robert Langreth

    A Breast Cancer Awareness ribbon in New York City. (Bloomberg) -- AstraZeneca Plc and Daiichi Sankyo Co.’s Enhertu delayed the advance of a common type of breast cancer by more than a year in a large study, a result that may lead to expanded use of the medicine. The treatment, already approved for several types of breast cancer, garnered sales of about $3.8 billion last year. It is routinely used as a second choice in roughly 20% of patients whose tumors have high levels of a protein called HER2.

  • 5 days ago | news.bloomberglaw.com | Robert Langreth |Damian Garde

    Drugs that boost the body’s immune system to fight disease are showing promise in treating a variety of cancers in earlier stages, a development primed to expand their use and transform care for stubborn diseases like gastric and colon cancer. Immunotherapy treatments such as Opdivo from Bristol Myers Squibb Co., Imfinzi from AstraZeneca PLC, and Roche Holding AG’s Tecentriq have become bestsellers by increasing survival times in a number of advanced cancers.

  • 5 days ago | bloomberg.com | Robert Langreth |Damian Garde

    Saline Drip Hanging On Metal Hook Against Wall In Hospital rf IV hospital(Bloomberg) -- Drugs that boost the body’s immune system to fight disease are showing promise in treating a variety of cancers in earlier stages, a development primed to expand their use and transform care for stubborn diseases like gastric and colon cancer.

  • 1 week ago | bloomberg.com | Robert Langreth

    Hi, its Bob in soggy New Jersey. I’m about to head to the big annual cancer conference in Chicago. How many of those new drugs save lives? More on that in a moment, but first ... I’ve been reporting on the FDA’s expedited drug approval process for a couple of years now. Critics say it’s helped drug companies make billions on drugs that turned out to be ineffective. And the cost of cancer drugs came up again and again.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
7K
Tweets
747
DMs Open
No
Robert Langreth
Robert Langreth @RobertLangreth
12 Feb 25

RT @SamHornblower: Alzheimer’s research has been stuck for decades—but is flawed science and research integrity part of the problem? Today…

Robert Langreth
Robert Langreth @RobertLangreth
10 Nov 23

RT @nncattan: If it works, “we will price it at a level that will democratize weight loss,” he said in an interview at Bloomberg headquarte…

Robert Langreth
Robert Langreth @RobertLangreth
10 Nov 23

RT @nncattan: AstraZeneca's Chief Executive Officer Pascal Soriot envisions his company bringing more affordable drugs to people who need t…